Acquisitions/mergers/joint-ventures/divestments   The boards of Pfizer and Allergan have agreed to merge their respective companies in a deal worth $155 billion and create the world largest pharma company with combined sales of over $60 billion. The new company will conduct business as Pfizer plc and will be domiciled in Ireland making it the largest “inversion” deal […]

  Two trends have become strikingly clear in the years since patents began expiring on the biopharmaceutical industry’s most lucrative products. First, companies have successfully taken steps to rebuild their pipelines with new products, many of which deliver real innovation to patients. Second, this innovation in science hasn’t been matched by an equal amount of […]

Acquisitions /mergers/joint-ventures   Pfizer is in final talks to acquire Allergan (Dublin, Ireland) in an all-stock transaction which would value Allergan at nearly $150 billion, the biggest health care deal ever. According to well-informed sources both companies are negotiating a break-up fee of 2-3% with an upper range at $4.5 billion, indicating that Pfizer does not […]

          BtoBioinnovation mourns the 132 people who were killed during the horrible terror attacks that took place last Friday in Paris. BtoBioinnovation also wishes to express its deepest sympathy, show its strong solidarity with the more than 450 people who were physically and psychologically wounded and with their respective families and […]

  Editor’s Note: Terror strikes again in Paris where more than 128 people were killed during several terrorist attacks on Friday, November 13. Several French political leaders appeal for unity and solidarity after “Act of War” while Isis claims responsibility.   Acquisitions /mergers/joint-ventures   Boston Scientific acquires CeloNova Biosciences (San Antonio, TX, USA), an interventional radiology […]

Acquisitions /mergers/joint-ventures   Shire acquires Dyax (Burlington, MA, USA) for $6.5 billion and gets access to DX-2930, an investigational hereditary angioedema drug (HEA), considered as a strong competitor to Shire’s own HEA portfolio such as Cinryze and Firazyr. HEA is a debilitating and potentially life-threatening rare genetic disease that causes swelling in the face, extremities and […]

Acquisitions /mergers/joint-ventures   Viropro (San Jose, CA, USA) has signed a non-binding letter of intent to acquire NovaRx (San Diego, CA, USA), a pioneer immuno-oncology company for an undisclosed all stock transaction. NovaRx has developed a proprietary method of activating the immune-system to recognize and destroy cancer cells. Viropro also indicated that it has begun the […]